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Background: Single-centre studies have shown that a low serum albumin at baseline forecasts enhanced mortality in chronic heart failure 
(CHF) possibly because it reflects aberrations (e.g inflammation, impaired nutrition, plasma volume expansion) that can exacerbate disease. We 
hypothesized that attenuations in serum albumin over time would be prognostically more ominous than baseline values, and would be so even in a 
multicentre setting.
Methods: We analysed the survival implications of baseline albumin and Δalbumin in a derivation cohort of 246 CHF outpatients (mean [±SD] 
age 68±12y, LVEF 29±8%, 48% NYHA class >2) from University College London Hospital and then in a validation cohort of 148 CHF outpatients (age 
69±12y, LVEF 28±10%, 41% NYHA class >2) from Imperial Healthcare (St Marys Hospital & Hammersmith Hospital, London).
Results: In the derivation cohort, 51 (21%) patients died over 13 months. Baseline albumin independently predicted mortality (HR 0.89, CI 0.84 - 
0.94, r2:18, P<0.0001). However, Δalbumin (unadjusted HR 0.89, CI 0.84 - 0.92, r2:53, P<0.0001) was even more predictive (Difference in ROC 
AUC for baseline vs Δalbumin 0.16, P<0.001) and did so independently of all covariates including baseline albumin. A reduction in albumin > 6 g/L 
optimally predicted death (ROC AUC 0.82, P<0.0001) and conferred a 6-fold escalated risk of mortality (HR 6.42, CI: 3.67 - 11.22, P<0.0001). In 
incremental prognostic analyses, the addition of Δalbumin to the strongest 4 variable model (baseline albumin, NYHA class, Δurea, Δhaemoglobin) 
dramatically augmented the r2 value (43 vs. 84, P<0.0001). In the validation cohort, 43 (30%) patients died. Δalbumin (unadjusted HR 0.89, CI 
0.86 - 0.92, r2:44, P<0.0001) was again prognostically superior to baseline albumin with a fall > 6 g/L predicting an ~ 6-fold increased risk (HR 
5.64, CI 3.08 - 10.31, r2:35, P<0.0001). Addition of Δalbumin to the strongest 3 variable model (baseline red cell distribution width, Δred cell 
distribution width, Δurea) also augmented the r2 value (51 vs. 65, P<0.001).
Conclusions: A fall in serum albumin over time consistently predicts an amplified risk of death in systolic CHF and enables simple and cheap risk 
stratification.
